ONCAlert | Upfront Therapy for mRCC

DLBCL VIEW MORE >>

Combining the antibody-drug conjugate polatuzumab vedotin with bendamustine and rituximab resulted in a significantly higher complete response rate in patients with transplantation-ineligible relapsed/refractory diffuse large B-cell lymphoma compared with patients who received BR alone. The international, multicenter, open-label, phase Ib/II trial also found that pola-BR reduced the risk of death by 58%, according to a recent Journal of Clinical Oncology paper.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.